Hot Features
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin ... Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0396 | -4.88888888889 | 0.81 | 0.8459 | 0.7502 | 41232 | 0.79149551 | CS |
| 4 | -0.1596 | -17.1612903226 | 0.93 | 0.987 | 0.7501 | 75117 | 0.87939306 | CS |
| 12 | -0.1596 | -17.1612903226 | 0.93 | 0.9995 | 0.4912 | 136689 | 0.76081706 | CS |
| 26 | -0.3496 | -31.2142857143 | 1.12 | 1.44 | 0.4912 | 264703 | 1.04764238 | CS |
| 52 | -0.2096 | -21.387755102 | 0.98 | 6.19 | 0.4912 | 706345 | 2.02009061 | CS |
| 156 | -3.3796 | -81.4361445783 | 4.15 | 8.99 | 0.4912 | 859696 | 1.60874772 | CS |
| 260 | -3.3796 | -81.4361445783 | 4.15 | 8.99 | 0.4912 | 859696 | 1.60874772 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.